Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VVOS Vivos Therapeutics

Closed 12-26 16:00:00 EST

4.76

-0.05

-1.04%

盘后4.75

-0.01-0.21%

19:59 EST

High4.89	Low4.53	Vol144.78K
Open4.82	D1 Closing4.81	Amplitude7.48%
Mkt Cap23.02M	Tradable Cap21.08M	Total Shares4.84M
T/O679.98K	T/O Rate3.27%	Tradable Shares4.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"VVOS","market":"US","secType":"STK","nameCN":"Vivos Therapeutics","latestPrice":4.76,"timestamp":1735246800000,"preClose":4.81,"halted":0,"volume":144775,"hourTrading":{"tag":"盘后","latestPrice":4.75,"preClose":4.76,"latestTime":"19:59 EST","volume":4579,"amount":22263.421,"timestamp":1735261172808},"delay":0,"floatShares":4428482,"shares":4835300,"eps":-3.52382,"marketStatus":"Closed","change":-0.05,"latestTime":"12-26 16:00:00 EST","open":4.82,"high":4.89,"low":4.53,"amount":679979.654325,"amplitude":0.074844,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.52382,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1735290000000},"marketStatusCode":5,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":4.81,"preHourTrading":{"tag":"盘前","latestPrice":4.8997,"preClose":4.81,"latestTime":"09:25 EST","volume":2077,"amount":10162.2818361,"timestamp":1735223113264},"postHourTrading":{"tag":"盘后","latestPrice":4.75,"preClose":4.76,"latestTime":"19:59 EST","volume":4579,"amount":22263.421,"timestamp":1735261172808},"volumeRatio":0.475116,"impliedVol":2.6041,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/VVOS/tweets","defaultTab":"tweets","newsList":[{"id":"2493093764","title":"Vivos Therapeutics Launches $3.5 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2493093764","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493093764?lang=en_us&edition=fundamental","pubTime":"2024-12-23 23:48","pubTimestamp":1734968893,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics  said Monday it has launched a registered direct offering of 709,220 common shares priced at $4.935 per share for gross proceeds of about $3.5 million.The company said it will issue unregistered short-term warrants in a concurrent private placement, allowing the purchase of up to 709,220 shares at an exercise price of $4.81 per share, with a two-year exercise period following the date of issuance.If fully exercised on a cash basis, the short-term warrants could generate nearly $3.4 million in additional gross proceeds for the company.The offering is expected to close around Tuesday, pending the fulfillment of customary closing conditions.Vivos said it plans to use the net proceeds from the offering for working capital and general corporate purposes.Shares of Vivos were down more than 7% in recent Monday trading.Price: 4.60, Change: -0.38, Percent Change: -7.59","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2493757948","title":"Vivos to sell 709,220 shares at $4.935 in registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2493757948","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493757948?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:15","pubTimestamp":1734959713,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics (VVOS) has entered into definitive agreements for the purchase and sale of an aggregate of 709,220 shares of its common stock at...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vivos-to-sell-709220-shares-at-4-935-in-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vivos-to-sell-709220-shares-at-4-935-in-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2493752537","title":"Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2493752537","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493752537?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:00","pubTimestamp":1734958801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nTUAW6BHK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4112","LU2210150020.SGD","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4196","VVOS","LU2095319765.USD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4588"],"gpt_icon":0},{"id":"2493752415","title":"Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2493752415","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493752415?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:00","pubTimestamp":1734958800,"startTime":"0","endTime":"0","summary":"LITTLETON, Colo., Dec.  23, 2024  (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the developme","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/23/3001200/0/en/Vivos-Therapeutics-Announces-3-5-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","VVOS","VIP","LU2095319765.USD","LU2210149790.SGD","BK4112","LU2210150020.SGD","NDAQ","IE00BGHQF748.EUR","PHH","IE00B3QW5Z07.USD","WRD","BK4196","IE00BKPKM429.USD",".IXIC","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2492815213","title":"All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2492815213","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492815213?lang=en_us&edition=fundamental","pubTime":"2024-12-19 01:00","pubTimestamp":1734541210,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics, Inc.  appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 . This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for Vivos Therapeutics basically reflects positivity about its earnings outlook that could translate into buying","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bHsRpCKrGzzbaGHEolBtWw--~B/aD02MTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bHsRpCKrGzzbaGHEolBtWw--~B/aD02MTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/know-vivos-therapeutics-vvos-rating-170010459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VVOS"],"gpt_icon":0},{"id":"2484220920","title":"Vivos Therapeutics Is Maintained at Buy by Alliance Global Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2484220920","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484220920?lang=en_us&edition=fundamental","pubTime":"2024-11-20 01:08","pubTimestamp":1732036080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VVOS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2024 12:08 ET (17:08 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS"],"gpt_icon":0},{"id":"2484398949","title":"Vivos Therapeutics Inc : Alliance Global Partners Cuts Target Price to $6 From $8.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2484398949","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484398949?lang=en_us&edition=fundamental","pubTime":"2024-11-19 21:10","pubTimestamp":1732021806,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nFWN3MQ0D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2484638203","title":"Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2484638203","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484638203?lang=en_us&edition=fundamental","pubTime":"2024-11-17 20:44","pubTimestamp":1731847489,"startTime":"0","endTime":"0","summary":"NasdaqCM:VVOS Earnings and Revenue Growth November 17th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 7.7%. Earnings per share  exceeded analyst estimates by 39%.Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Healthcare industry in the US.The company's shares are down 8.1% from a week ago.You still need to take note of risks, for example - Vivos Therapeutics has   5 warning signs    we think you should know about.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vivos-therapeutics-third-quarter-2024-124449950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VVOS"],"gpt_icon":0},{"id":"2483714863","title":"Vivos Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483714863","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483714863?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:13","pubTimestamp":1731680010,"startTime":"0","endTime":"0","summary":"* Vivos Therapeutics Inc    reported a quarterly adjusted loss of 40 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.62","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Vivos Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS"],"gpt_icon":0},{"id":"2483418923","title":"Vivos Therapeutics Inc (VVOS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483418923","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483418923?lang=en_us&edition=fundamental","pubTime":"2024-11-15 17:00","pubTimestamp":1731661226,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Vivos Therapeutics Inc  reported a 17% increase in total revenue for Q3 2024 compared to the same period in 2023, driven by higher sales of Vivos appliances and guides.The company achieved a 34% increase in product revenue and a 60% gross margin for Q3 2024, up from 53% in Q3 2023.The company has strengthened its cash position, with cash and cash equivalents increasing to $6.3 million as of September 30, 2024, compared to $1.6 million at the end of 2023.GuruFocus has detected 4 Warning Signs with VVOS.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vivos-therapeutics-inc-vvos-q3-090026198.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VVOS"],"gpt_icon":0},{"id":"2483391270","title":"Vivos Therapeutics Reports Revenue Growth and Strategic Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2483391270","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483391270?lang=en_us&edition=fundamental","pubTime":"2024-11-15 12:19","pubTimestamp":1731644384,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics, Inc. ( ($VVOS) ) has released its Q3 earnings. Here is a breakdown of the information Vivos Therapeutics, Inc. presented to its...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-reports-revenue-growth-and-strategic-milestones?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-reports-revenue-growth-and-strategic-milestones?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS"],"gpt_icon":0},{"id":"2483358720","title":"Vivos Therapeutics Q3 2024 GAAP EPS $(0.40) Beats $(0.79) Estimate, Sales $3.860M Miss $4.061M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483358720","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483358720?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:36","pubTimestamp":1731620184,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.79) by 49.37 percent.  The company reported quarterly sales of $3.860 million which missed","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41991684/vivos-therapeutics-q3-2024-gaap-eps-0-40-beats-0-79-estimate-sales-3-860m-miss-4-061m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Vivos Therapeutics Q3 2024 GAAP EPS $(0.40) Beats $(0.79) Estimate, Sales $3.860M Miss $4.061M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS"],"gpt_icon":0},{"id":"2483633769","title":"Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483633769","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483633769?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:05","pubTimestamp":1731618303,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA29QLSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2483967337","title":"Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483967337","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483967337?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:05","pubTimestamp":1731618300,"startTime":"0","endTime":"0","summary":"Management to Host Conference Call Today at 5:00 pm ET. LITTLETON, Colo., Nov. 14, 2024  -- Vivos Therapeutics, Inc.  , a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders , today reported financial results and operating highlights for the third quarter and nine months ended September 30, 2024.Revenue was $3.9 million for the third quarter of 2024 and $11.3 million for the nine months ended September 30, 2024, compared to $3.3 million and $10.6 million for the three and nine months ended September 30, 2023, respectively, mainly due to increased revenue from higher product sales and lower discounts of Vivos appliances coupled with higher service revenue primarily from early recognition of deferred enrollment revenue, sponsorships and seminars, offset by lower myofunctional therapy revenues.As of September 30, 2024, patients treated with Vivos’ patented oral ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MibYRvHJ2.efCvD2LspdMg--~B/aD00Njt3PTE0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/725d8fbec3d3dd0dfd7f58221775bf79","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MibYRvHJ2.efCvD2LspdMg--~B/aD00Njt3PTE0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/725d8fbec3d3dd0dfd7f58221775bf79"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vivos-therapeutics-reports-third-quarter-210500227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VIP","OSA","BK4196","VVOS","BK4082"],"gpt_icon":1},{"id":"2483667048","title":"Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2483667048","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483667048?lang=en_us&edition=fundamental","pubTime":"2024-11-14 06:00","pubTimestamp":1731535200,"startTime":"0","endTime":"0","summary":"LITTLETON, Colo., Nov. 13, 2024  -- Vivos Therapeutics, Inc.  , a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders , today announced it plans to release its third quarter 2024 financial results after market close on Thursday, November 14, 2024.Vivos’ management will conduct a conference call at 5:00 p.m.  on November 14, 2024 to review the results and provide an overview of Vivos’ recent achievements and developments.Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea  and snoring in adults and children. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical, and cost-effective solution f","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MibYRvHJ2.efCvD2LspdMg--~B/aD00Njt3PTE0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/725d8fbec3d3dd0dfd7f58221775bf79","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MibYRvHJ2.efCvD2LspdMg--~B/aD00Njt3PTE0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/725d8fbec3d3dd0dfd7f58221775bf79"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vivos-therapeutics-schedules-release-third-220000490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OSA","VIP","BK4082","BK4196","VVOS"],"gpt_icon":1},{"id":"2482808148","title":"Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely","url":"https://stock-news.laohu8.com/highlight/detail?id=2482808148","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482808148?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:53","pubTimestamp":1731412435,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shares have continued their recent momentum with a 27% gain in the last month...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-vvos/vivos-therapeutics/news/even-with-a-27-surge-cautious-investors-are-not-rewarding-vi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2210150020.SGD","SQQQ","PSQ","IE00BGHQF748.EUR","QLD","MNQmain","QID","VVOS",".IXIC","BK4211","IE00BKPKM429.USD","BK4588","BK4196","BK4585","IE00B64PRP62.GBP","NQmain","NDAQ","LU2095319765.USD","BK4112","ISBC","LU2210149790.SGD","TQQQ","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2482845241","title":"Vivos Therapeutics Inc    expected to post a loss of 61 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482845241","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482845241?lang=en_us&edition=fundamental","pubTime":"2024-11-09 06:22","pubTimestamp":1731104557,"startTime":"0","endTime":"0","summary":"* Vivos Therapeutics Inc     is expected to show a rise in quarterly revenue when it reports  results on November 12 (estimated) for the period ending September 30 2024   * The Littleton Colorado-base","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vivos Therapeutics Inc    expected to post a loss of 61 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS"],"gpt_icon":0},{"id":"2473842344","title":"Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association","url":"https://stock-news.laohu8.com/highlight/detail?id=2473842344","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473842344?lang=en_us&edition=fundamental","pubTime":"2024-10-08 19:30","pubTimestamp":1728387000,"startTime":"0","endTime":"0","summary":"New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and ChildrenLITTLETON, Colo., Oct.  08, 2024  (GLOBE NEWSWIRE) -- Vivos Th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/08/2959585/0/en/Vivos-Therapeutics-Granted-CPT-Coverage-and-Reimbursement-Codes-for-All-Vivos-CARE-Oral-Medical-Devices-From-American-Medical-Association.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","VVOS","VIP","BK4585","CARE","BK4107","CPT","BK4117","BK4215","AFG","BK4588","BK4196"],"gpt_icon":0},{"id":"2468650726","title":"Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2468650726","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468650726?lang=en_us&edition=fundamental","pubTime":"2024-09-20 00:39","pubTimestamp":1726763967,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/09/40943940/dow-jumps-over-500-points-factset-research-posts-upbeat-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HAO","FDS","SGN","PGNY","MBLY","VVOS","PCOM","EWTX"],"gpt_icon":0},{"id":"2468250614","title":"Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2468250614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468250614?lang=en_us&edition=fundamental","pubTime":"2024-09-19 23:06","pubTimestamp":1726758360,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics shares dropped Thursday after the company said it is offering 1.4 million common shares at $3.15 per share in a registered direct offering.Shares were down 27% to $3.03 in recent trading after closing at $4.13 on Wednesday. The stock is down almost 76% this year.The offering is expected to close by Friday.The Colorado company said it expects to see about $4.3 million in proceeds from the offering before fees and expenses. It currently intends to use the net proceeds for working capital and general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vivos.com","stockEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.5031},{"period":"3month","weight":0.4846},{"period":"6month","weight":1.0126},{"period":"1year","weight":-0.5755},{"period":"ytd","weight":-0.6133}],"compareEarnings":[{"period":"1week","weight":-0.0049},{"period":"1month","weight":0.0097},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.1005},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.2651}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.377066},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037873},{"month":3,"riseRate":0,"avgChangeRate":-0.230737},{"month":4,"riseRate":0.5,"avgChangeRate":-0.19387},{"month":5,"riseRate":0.5,"avgChangeRate":-0.029275},{"month":6,"riseRate":0.5,"avgChangeRate":-0.011445},{"month":7,"riseRate":0.25,"avgChangeRate":-0.222928},{"month":8,"riseRate":0.75,"avgChangeRate":0.213255},{"month":9,"riseRate":0,"avgChangeRate":-0.24401},{"month":10,"riseRate":0.25,"avgChangeRate":-0.089926},{"month":11,"riseRate":0.5,"avgChangeRate":1.595624},{"month":12,"riseRate":0.25,"avgChangeRate":-0.098834}],"exchange":"NASDAQ","name":"Vivos Therapeutics","nameEN":"Vivos Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vivos Therapeutics(VVOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vivos Therapeutics,VVOS,Vivos Therapeutics股票,Vivos Therapeutics股票老虎,Vivos Therapeutics股票老虎国际,Vivos Therapeutics行情,Vivos Therapeutics股票行情,Vivos Therapeutics股价,Vivos Therapeutics股市,Vivos Therapeutics股票价格,Vivos Therapeutics股票交易,Vivos Therapeutics股票购买,Vivos Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vivos Therapeutics(VVOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction